Rigel Announces Presentations at the 2007 American Society of Hematology (ASH) Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a number of presentations being given on Rigel product candidates at the upcoming American Society of Hematology Meeting and Exposition, at the Georgia World Congress Center in Atlanta, Georgia, December 8-11, 2007.
Rigel Poster Presentations R935788: A phase 2, single center, open label, efficacy and safety, ascending dose, pilot study for the treatment of adult Immune Thrombocytopenic Purpura (ITP) Saturday, December 8, 2007 5:30 p.m. - 7:30 p.m. Session Name -- ITP, TTP and HIT Poster #464 Targeting myeloproliferative diseases with JAK2 inhibitors Monday, December 10, 2007 5:00 p.m. - 7:00 p.m. Session Name -- Myeloproliferative Syndromes: Therapy Poster #769 Merck Serono Poster Presentation on Rigel's R763/AS703569 The novel aurora kinase inhibitor AS703569 shows potent anti-tumor activity in Acute Myeloid Leukemia (AML) Saturday, December 8, 2007 5:30 p.m. - 7:30 p.m. Session Name - Acute Myeloid Leukemias: Therapy, excluding Transplantation Poster #69 Other collaboration presentations with Rigel product candidates Syk kinase inhibition by R406 inhibits BCR mediated B cell proliferation and interferes with BCR signal transduction in primary tumor samples Oral Presentation -- Tuesday, December 11, 2007 8:15 a.m. Session Name -- Lymphoma: Pre-Clinical Chemotherapy and Biologic Agents -- Novel Agents, including Small Molecule Inhibitors Mechanistic paradigm for combination signal transduction inhibitor therapy in Zap70+ CLL involves bicompartmental functions of EZH2 Monday, December 10, 2007 5:00 p.m. - 7:00 p.m. Session Name -- CLL: Clinical Biology Poster #318 Constitutive activation of the protein tyrosine kinase syk in chronic lymphocytic leukemia B cells Saturday, December 8, 2007 5:30 p.m. - 7:30 p.m. Session Name -- CLL: Molecular Biology Poster #277
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
This press release contains "forward-looking" statements, including statements related to the potential efficacy of Rigel's product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "goal" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-Q for the quarter ended September 30, 2007. Rigel does not undertake any obligation to update forward-looking statements.
Contact: Raul Rodriguez Phone: 650.624.1302 Email: firstname.lastname@example.org Media Contact: Susan C. Rogers, Alchemy Consulting, Inc. Phone: 650.430.3777 Email: email@example.com
SOURCE Rigel Pharmaceuticals, Inc.
Released December 5, 2007